JP2023550203A5 - - Google Patents
Info
- Publication number
- JP2023550203A5 JP2023550203A5 JP2023548542A JP2023548542A JP2023550203A5 JP 2023550203 A5 JP2023550203 A5 JP 2023550203A5 JP 2023548542 A JP2023548542 A JP 2023548542A JP 2023548542 A JP2023548542 A JP 2023548542A JP 2023550203 A5 JP2023550203 A5 JP 2023550203A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- composition
- approximately
- concentration
- rigf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063093696P | 2020-10-19 | 2020-10-19 | |
| US63/093,696 | 2020-10-19 | ||
| PCT/US2021/055598 WO2022086953A1 (en) | 2020-10-19 | 2021-10-19 | Compositions suitable for use in neonates |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023550203A JP2023550203A (ja) | 2023-11-30 |
| JP2023550203A5 true JP2023550203A5 (enExample) | 2024-09-30 |
| JP7827315B2 JP7827315B2 (ja) | 2026-03-10 |
Family
ID=78622033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023548542A Active JP7827315B2 (ja) | 2020-10-19 | 2021-10-19 | 新生児における使用に好適な組成物 |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20230381285A1 (enExample) |
| EP (2) | EP4534073A3 (enExample) |
| JP (1) | JP7827315B2 (enExample) |
| KR (1) | KR20230113287A (enExample) |
| CN (1) | CN117098547A (enExample) |
| AU (1) | AU2021364523A1 (enExample) |
| CA (1) | CA3194764A1 (enExample) |
| DK (1) | DK4228676T3 (enExample) |
| ES (1) | ES3005966T3 (enExample) |
| FI (1) | FI4228676T3 (enExample) |
| HR (1) | HRP20250193T1 (enExample) |
| HU (1) | HUE070409T2 (enExample) |
| IL (1) | IL301688A (enExample) |
| LT (1) | LT4228676T (enExample) |
| MX (1) | MX2023004426A (enExample) |
| PL (1) | PL4228676T3 (enExample) |
| PT (1) | PT4228676T (enExample) |
| RS (1) | RS66493B1 (enExample) |
| SA (1) | SA523440271B1 (enExample) |
| SI (1) | SI4228676T1 (enExample) |
| SM (1) | SMT202500093T1 (enExample) |
| TW (1) | TWI912393B (enExample) |
| WO (1) | WO2022086953A1 (enExample) |
| ZA (1) | ZA202303162B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025502349A (ja) | 2022-01-19 | 2025-01-24 | オーク ヒル バイオ リミテッド | Ｉｇｆ－１／ｉｇｆｂｐの酸化を低減するための組成物および方法 |
| IL316413A (en) | 2022-05-04 | 2024-12-01 | Oak Hill Bio Ltd | Combination therapy for preterm infants |
| WO2023242439A1 (en) * | 2022-06-17 | 2023-12-21 | Oak Hill Bio Limited | Vascular stabilisation (preterm infants) |
| WO2023242440A1 (en) * | 2022-06-17 | 2023-12-21 | Oak Hill Bio Limited | Treament of lungs in infants |
| KR20250079196A (ko) * | 2022-10-04 | 2025-06-04 | 오크 힐 바이오 리미티드 | Igf-1 복합체를 이용한 신생아 치료 방법 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL71991A (en) | 1983-06-06 | 1994-05-30 | Genentech Inc | Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes |
| AU627423B2 (en) | 1987-04-06 | 1992-08-27 | Celtrix Pharmaceuticals, Inc. | Human somatomedin carrier protein subunits and process for producing them |
| DK131988A (da) | 1988-03-11 | 1989-09-12 | Erasmus University | Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur |
| US5258287A (en) | 1988-03-22 | 1993-11-02 | Genentech, Inc. | DNA encoding and methods of production of insulin-like growth factor binding protein BP53 |
| DE3854842T2 (de) | 1988-04-12 | 1996-06-13 | Amgen Boulder Inc | Verfahren zur steigerung und zur hemmung der wirkung eines insulinähnlichen wachstumfaktors |
| GB8826451D0 (en) | 1988-11-11 | 1988-12-14 | Sandoz Ltd | Improvements in/relating to organic compounds |
| IL92816A0 (en) | 1988-12-22 | 1990-09-17 | Biogrowth Inc | Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides |
| AU4238493A (en) | 1992-05-08 | 1993-12-13 | Thomas Jefferson University | IGF-1 analogs |
| US5563046A (en) | 1993-08-02 | 1996-10-08 | Celtrix Pharmaceuticals, Inc. | Fusion polypeptides and proteins |
| US5789547A (en) | 1995-06-07 | 1998-08-04 | Celtrix Pharmaceuticals, Inc. | Method of producing insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) with correct folding and disulfide bonding |
| US5783556A (en) * | 1996-08-13 | 1998-07-21 | Genentech, Inc. | Formulated insulin-containing composition |
| US5985830A (en) * | 1996-09-16 | 1999-11-16 | Dalhousie University | Use of IGF-I for the treatment of kidney disorders |
| US6121416A (en) | 1997-04-04 | 2000-09-19 | Genentech, Inc. | Insulin-like growth factor agonist molecules |
| US6436897B2 (en) * | 1998-06-01 | 2002-08-20 | Celtrix Pharmaceuticals, Inc. | Pharmaceutical formulations for IGF/IGFBP |
| US20020028764A1 (en) * | 2000-09-04 | 2002-03-07 | Aarhus Amt. | Treatment of acute and chronic liver disease |
| WO2006138181A2 (en) * | 2005-06-14 | 2006-12-28 | Amgen Inc. | Self-buffering protein formulations |
| EP2501367B1 (en) * | 2009-11-17 | 2015-01-21 | Ipsen Pharma S.A.S. | Formulation for HGH and RHIGF-1 combination |
| HK1217633A1 (zh) * | 2013-01-15 | 2017-01-20 | Teva Pharmaceutical Industries Ltd. | 冻乾方法 |
| KR20140119396A (ko) * | 2013-03-29 | 2014-10-10 | 삼성전자주식회사 | 단백질 약물의 액상 제형 |
| KR20200097679A (ko) * | 2017-09-11 | 2020-08-19 | 샤이어 휴먼 지네틱 테라피즈 인크. | 만성 폐 질환 치료를 위한 방법 및 조성물 |
| JP2025502349A (ja) * | 2022-01-19 | 2025-01-24 | オーク ヒル バイオ リミテッド | Ｉｇｆ－１／ｉｇｆｂｐの酸化を低減するための組成物および方法 |
| WO2023139250A1 (en) * | 2022-01-24 | 2023-07-27 | Oak Hill Bio Limited | Lot release assays for igf‐1/igfbp complexes |
-
2021
- 2021-10-19 ES ES21807381T patent/ES3005966T3/es active Active
- 2021-10-19 PT PT218073815T patent/PT4228676T/pt unknown
- 2021-10-19 AU AU2021364523A patent/AU2021364523A1/en active Pending
- 2021-10-19 EP EP24221637.2A patent/EP4534073A3/en active Pending
- 2021-10-19 CA CA3194764A patent/CA3194764A1/en active Pending
- 2021-10-19 FI FIEP21807381.5T patent/FI4228676T3/fi active
- 2021-10-19 SI SI202130265T patent/SI4228676T1/sl unknown
- 2021-10-19 EP EP21807381.5A patent/EP4228676B1/en active Active
- 2021-10-19 SM SM20250093T patent/SMT202500093T1/it unknown
- 2021-10-19 RS RS20250138A patent/RS66493B1/sr unknown
- 2021-10-19 TW TW110138769A patent/TWI912393B/zh active
- 2021-10-19 CN CN202180071124.7A patent/CN117098547A/zh active Pending
- 2021-10-19 HU HUE21807381A patent/HUE070409T2/hu unknown
- 2021-10-19 DK DK21807381.5T patent/DK4228676T3/da active
- 2021-10-19 KR KR1020237016217A patent/KR20230113287A/ko active Pending
- 2021-10-19 WO PCT/US2021/055598 patent/WO2022086953A1/en not_active Ceased
- 2021-10-19 HR HRP20250193TT patent/HRP20250193T1/hr unknown
- 2021-10-19 US US18/249,414 patent/US20230381285A1/en active Pending
- 2021-10-19 PL PL21807381.5T patent/PL4228676T3/pl unknown
- 2021-10-19 IL IL301688A patent/IL301688A/en unknown
- 2021-10-19 MX MX2023004426A patent/MX2023004426A/es unknown
- 2021-10-19 LT LTEPPCT/US2021/055598T patent/LT4228676T/lt unknown
- 2021-10-19 JP JP2023548542A patent/JP7827315B2/ja active Active
-
2023
- 2023-02-28 ZA ZA2023/03162A patent/ZA202303162B/en unknown
- 2023-04-06 SA SA523440271A patent/SA523440271B1/ar unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2393180T3 (es) | Preparados de insulina libre de cinc o con bajo contenido en cinc con estabilidad mejorada | |
| JP7202272B2 (ja) | インスリン分泌性ペプチドの安定な水性非経口医薬組成物 | |
| US6034054A (en) | Stable insulin formulations | |
| JP4589018B2 (ja) | エリスロポエチン溶液製剤 | |
| KR100266502B1 (ko) | 성장호르몬과히스티딘으로이루어지는안정화된약학제제 | |
| US5849700A (en) | Pharmaceutical formulation | |
| FI4228676T3 (fi) | Koostumuksia, jotka sopivat vastasyntyneillä käytettäviksi | |
| EP0921812B1 (en) | Insulin preparations containing a halogenide | |
| US20080248999A1 (en) | Amylin formulations | |
| WO2012130136A1 (zh) | 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用 | |
| ES2391776T3 (es) | Formulaciones solubles, estables conteniendo insulina con una sal de protamina | |
| JP2001199899A (ja) | インスリン類似化合物複合体 | |
| JP2024156754A5 (enExample) | ||
| KR20000076419A (ko) | 폐 투여용 무아연 인슐린 결정 조성물 | |
| JP2002500196A (ja) | 安定化させたインスリン組成物 | |
| JPWO2001064241A1 (ja) | 長期安定化製剤 | |
| KR20150021011A (ko) | 초고도 농축된, 속효성 인슐린 유사체 제형 | |
| JP2002512973A (ja) | タンパク質製剤 | |
| JP2022549328A5 (enExample) | ||
| JP2021511362A5 (enExample) | ||
| CA1335924C (en) | Mixed crystals of insulin and insulin derivatives, a process for the preparation of these mixed crystals, pharmaceutical agents containing these mixed crystals, and the use thereof for the treatment of diabetes mellitus | |
| JP2010523501A (ja) | Ｇｈｒｈ分子の医薬製剤 | |
| JP2025114869A5 (enExample) | ||
| EP1283051B1 (en) | Stable insulin formulations | |
| CA2589889A1 (en) | Therapeutic formulations of keratinocyte growth factor |